June 5, 2024Open Access

Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis

Key Points

Key points are not available for this paper at this time.

Abstract

Pembrolizumab and dostarlimab are immune checkpoint inhibitors that target programmed death receptor 1 (PD-1). Combination anti-PD-1 regimens have been shown to exhibit favorable survival benefits when treating advanced endometrial cancer (EC). Which treatment was preferable will need to be confirmed by a cost-effectiveness comparison between them.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Youwen Zhu

Fujian Medical University

Kun Liu

Second Military Medical University

Hong Zhu

University of South Florida

Journals

Journal of Gynecologic Oncology

Actions

Institutions

Central South University

Xiangya Hospital Central South University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study